WuXi AppTec Receives AA ESG Rating from MSCI
SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...
WuXi AppTec Reports Strong 2021 Interim Results
* Revenue Up 45.7% Year-Over-Year to RMB10,537 Million * Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million * Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 * Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-...
WuXi AppTec Reports Strong 2020 Annual Results
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year toRMB3,565 Mil...
WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award
SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has received the 2020 Global Customer Value Leadership Award from Frost & Sullivan, ...
WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations
WuXi AppTec Second-Quarter 2020 Results Revenue Up 29.4% YoY to RMB4,044 Million Net Profit Attributable to Owners of the Company Up 111.0% YoY to RMB1,414 Million Diluted EPS Up 110.3% YoY to RMB0.61 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 43.1% YoY toRMB942 Million...
WuXi AppTec Reports Solid First-Quarter 2020 Results
SHANGHAI, April 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and del...
WuXi AppTec Reports Strong 2019 Annual Results
Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year toRMB2,407 Million Adjusted Diluted Non-IFRS EPS Up by 19.7% to RMB1.46[1] SHANGHAI, March 24, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. ...
WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform
PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully ...
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility
SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- STA Pharmaceutical Co., Ltd.,
WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies
SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec. Th...
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...
WuXi AppTec Reports First Half 2019 Interim Results
* Revenue Accelerated 33.7% Year-Over-Year to RMB 5,894 Million * Gross Profit Up 30.0% Year-Over-Year to RMB 2,284 million[1] * Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year toRMB 1,179 Million * Small Molecule CDMO/CMO Pipeline has Grown to 800...
WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections
SHANGHAI, July 23, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) inShanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two...
WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies
SHANGHAI, June 29, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its ded...
